Recurrent Verrucous Carcinoma of the Larynx Completed Phase 2 Trials for Dasatinib (DB01254)

Also known as: Laryngeal verrucous carcinoma recurrent / Recurrent Laryngeal Verrucous Carcinoma / Squamous Cell Carcinoma of the Larynx / Laryngeal squamous cell carcinoma / Primary squamous cell carcinoma of larynx (disorder) / Squamous cell carcinoma of larynx (disorder)

IndicationStatusPhase
DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00507767Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerTreatment